nach oben

Erschienen in:

01.08.2004 | Original

Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy

verfasst von: Verena Eggers, Katja Fügener, Ortrud Vargas Hein, Hans Rommelspacher, Melvyn P. Heyes, Wolfgang J. Kox, Claudia D. Spies

Erschienen in: Intensive Care Medicine | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate antibiotic-mediated release of tumour necrosis factor (TNF)-α and norharman in patients with hospital-acquired pneumonia with and without additional septic encephalopathy.

Design

Prospective observational study with a retrospective post hoc analysis.

Setting

Surgical intensive care unit (ICU) at a university hospital.

Patients

Thirty-seven patients were consecutively included (9 patients with hospital-acquired pneumonia, 11 patients with hospital-acquired pneumonia and septic encephalopathy, 17 control patients) in the study. Pneumonia was defined according to the criteria of the American Thoracic Society.

Interventions

Patients received cephalosporins for antibiotic treatment of hospital-acquired pneumonia. Blood samples were taken before, immediately after and 4 h after application of cephalosporins.

Measurements and results

Of the pneumonia patients, 55% developed septic encephalopathy. ICU stay, complications and mortality were significantly increased. An increased release of TNF-α was immediately seen in all pneumonia patients after antibiotics compared to controls, whereas the level did not differ between patients with and without septic encephalopathy. Norharman was significantly increased in pneumonia patients 4 h after antibiotic treatment, in tendency more enhanced in the pneumonia patients without encephalopathy.

Conclusions

Patients with hospital-acquired pneumonia and septic encephalopathy had a significantly longer ICU stay with higher mortality rate compared to patients with hospital-acquired pneumonia alone. Antibiotic-mediated TNF-α release may induce the kynurenine pathway. TNF-α activates indolamine-2,3-dioxygenase with neurotoxic quinolinic acid as the end product. Norharman seems to counteract this mechanism and seems to play a role in neuroprotection. The worse outcome of patients with encephalopathy expresses the need to investigate protective factors and mechanisms.

Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27:887–892PubMed

Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903

Bolton CF, Young GB, Zochodne DW (1993) The neurological complications of sepsis. Ann Neurol 33:94–100PubMed

Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155PubMed

Gelfand JA, Elin RJ, Berry FW (1976) Endotoxemia associated with the Jarisch-Herxheimer reaction. N Engl J Med 295:211–213PubMed

Lepper PM, Held TK, Schneider EM, Bolke E, Gerlach H, Trautmann M (2002) Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 28:824–833CrossRef

Eguchi N, Watanabe Y, Kawanishi K, Hashimoto Y, Hayaishi O (1984) Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch Biochem Biophys 232:602–609PubMed

Heyes MP, Saito K, Crowley JS (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:1249–1273PubMed

Heyes MP, Chen CY, Major EO, Saito K (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326:351–356PubMed

10.

Saito K, Chen CY, Heyes MP (1993) 4-chloro-3hydroxyanthranilate, 6-chlorotryptophan and norharman attenuate quinolinic acid formation by interferon-γ-stimulated monocytes (THP-1 cells). Biochem J 291:11–14PubMed

11.

Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379PubMed

12.

Rommelspacher H, Meier-Henco M, Smolka M, Kloft C (2002) The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur J Pharmacol 441:115–125CrossRefPubMed

13.

Fekkes D, Tuiten A, Bom I, Pepplinkhuizen L (2001) Tryptophan: a precursor for the endogenous synthesis of norharman in man. Neurosci Lett 303:145–148CrossRefPubMed

14.

Spies CD, Rommelspacher H, Schnapper C, Muller C, Marks C, Berger G, Conrad C, Blum S, Specht M, Hannemann L et al. (1995) Beta-carbolines in chronic alcoholics undergoing elective tumor resection. Alcohol Clin Exp Res 19:969–976PubMed

15.

Aleo MD, Schnellmann RG (1992) The neurotoxicants strychnine and bicuculline protect renal proximal tubules from mitochondrial inhibitor-induced cell death. Life Sci 51:1783–1787CrossRefPubMed

16.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMed

17.

Goris RJA, Boekhorst TPA, Nuytinck JKS (1985) Multiple organ failure. Arch Surg 120:109–115

18.

Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 2:81–84PubMed

19.

Garner JS, Jarvis WR, Emori TG (1988) CDC definitions for nosocomial infections. J Infect Control 16:128–140PubMed

20.

Anonymous (1996) Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 153:1511–1725

21.

Members of the American College of Chest Physicans/Society of Critical Care Medicine Consensus Conference Committee (1992) American College of Chest Physicans/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874PubMed

22.

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4^th edn. Washington DC

23.

Eggers V, Schilling A, Kox WJ, Spies C (2003) Septic encephalopathy. Diagnosis and therapy. Anaesthesist 52:294–303PubMed

24.

Prins JM, van Agtmael MA, Kuijper ED (1995) Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis 172:886–891PubMed

25.

Dofferhoff AS, Esselink MT, de Vries-Hospers HG, van Zanten A, Bom VJ, Weits J, Vellenga E (1993) The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother 31:373–384PubMed

26.

Mock CN, Jurkovich GJ, Dries DJ, Maier RV (1995) Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 130:1234–1240PubMed

27.

Simon DM, Koenig G, Trenholme GM (1991) Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli. J Infect Dis 164:800–802PubMed

28.

Silverstein R, Wood JG, Xue Q (2000) Differential host inflammatory response to viable versus antibiotic-killed bacteria in experimental microbial sepsis. Infect Immun 68:2301–2308CrossRefPubMed

29.

Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH (2001) Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 17:497–504CrossRefPubMed

30.

Standiford TJ, Kunkel SL, Strieter RM (1991) Elevated serum levels of tumor necrosis factor after bronchoscopy and bronchoalveolar lavage. Chest 99:1529–1530PubMed

31.

Pugin J, Suter PM (1992) Diagnostic bronchoalveolar lavage in patients with pneumonia produces sepsis-like effects. Intensive Care Med 18:6–10PubMed

32.

Heyes MP, Brew BJ, Martin A (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 29:202–209PubMed

33.

Basler T, Meier-Hellmann A, Bredle D, Reinhart K (2002) Amino acid imbalance early in septic encephalopathy. Intensive Care Med 28:293–298CrossRef

34.

Badaway AA, Rommelspacher H, Morgan CJ, Bradley DM, Bonner A, Ehlert A, Blum S, Spies CD (1998) Tryptophan metabolism in alcoholism. Tryptophan but not excitatory amino acid availability to the brain is increased before the appearance of the alcohol-withdrawal syndrome in the men. Alcohol Alcohol 34:616–625

35.

Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY (2001) Tumor necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. J Med Microbiol 50:812–821PubMed

36.

Stuber F, Wrigge H, Schroeder S, Wetegrove S, Zinserling J, Hoeft A, Putensen C (2002) Kinetics and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med 28:834–841CrossRef

Titel: Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy
verfasst von: Verena Eggers
Katja Fügener
Ortrud Vargas Hein
Hans Rommelspacher
Melvyn P. Heyes
Wolfgang J. Kox
Claudia D. Spies
Publikationsdatum: 01.08.2004
Verlag: Springer-Verlag
Erschienen in: Intensive Care Medicine / Ausgabe 8/2004
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-004-2285-6

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy